- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| TRISALUS LIFE SCIENCES Aktie jetzt für 0€ handeln | |||||
| Do | Canaccord reiterates TriSalus stock Buy rating after KOL event | 1 | Investing.com | ||
| 18.05. | TriSalus Life Sciences: Aktie steigt trotz Umsatzrückgang im ersten Quartal 2026 | 1 | Investing.com Deutsch | ||
| 13.05. | TriSalus outlines $54M-$57M 2026 revenue forecast while TriNav Advance clearance runs ~5 months past goal | 1 | Seeking Alpha | ||
| 12.05. | TriSalus Life Sciences Q1 2026 Earnings Call: Complete Transcript | 2 | Benzinga.com | ||
| 12.05. | TriSalus Life Sciences GAAP EPS of $0.03 beats by $0.19, revenue of $8.9M misses by $1.54M | 2 | Seeking Alpha | ||
| 12.05. | TriSalus senkt Umsatzprognose für 2026 auf 54-57 Mio. US-Dollar | 3 | Investing.com Deutsch | ||
| 12.05. | TriSalus Life Sciences, Inc. - 10-Q, Quarterly Report | 2 | SEC Filings | ||
| 04.05. | TriSalus startet PREDICTT-Studie zur Behandlung von Lebertumoren | 1 | Investing.com Deutsch | ||
| 04.05. | TriSalus initiates PREDICTT trial for liver tumor treatment | 1 | Investing.com | ||
| 09.04. | TriSalus to present drug delivery data at radiology meeting | 1 | Investing.com | ||
| 07.04. | TriSalus ernennt Richard Marshall zum Chief Medical Officer | 2 | Investing.com Deutsch | ||
| 07.04. | TriSalus names Richard Marshall as chief medical officer | 2 | Investing.com | ||
| 07.04. | TriSalus Life Sciences, Inc. - 8-K, Current Report | - | SEC Filings | ||
| 18.03. | TriSalus publishes preclinical data on drug delivery technology | 1 | Investing.com | ||
| 06.03. | Jones Trading bestätigt Kaufempfehlung für TriSalus Life Sciences nach Geschäftszahlen | 1 | Investing.com Deutsch | ||
| 06.03. | Jones Trading reiterates Buy on TriSalus Life Sciences stock after earnings | 2 | Investing.com | ||
| 06.03. | TriSalus Life Sciences reaffirms $60M-$62M revenue guidance for 2026 while expanding PEDD portfolio | 1 | Seeking Alpha | ||
| 05.03. | TriSalus Life Sciences: Umsatz steigt im vierten Quartal um 60 % | 3 | Investing.com Deutsch | ||
| 05.03. | TriSalus Life Sciences, Inc. - 10-K, Annual Report | 1 | SEC Filings | ||
| 05.03. | Earnings Summary: TriSalus Life Sciences Q4 | 1 | Benzinga.com |
1 2 Weiter >>
33 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| TILRAY BRANDS | 3,915 | -0,38 % | Tilray Brands, Inc.: Hi*Ball Energy erobert Großbritannien und wird zum Vorreiter des neuen "Clean Energy"-Trends | Neue Energie tanken mit Hi*Ball Sparkling Energy Water: Der innovative Energydrink kombiniert natürliches Koffein und funktionelle Inhaltsstoffe mit vollem Geschmack - ohne Zucker, ohne Kalorien und... ► Artikel lesen | |
| VIATRIS | 14,238 | +0,74 % | VTRS vs. DHR: Which Stock Is the Better Value Option? | ||
| SYNBIOTIC | 1,100 | +7,21 % | EQS-Adhoc: SYNBIOTIC SE: Hempro International GmbH beabsichtigt Antrag auf Eröffnung eines vorläufigen Insolvenzverfahrens | EQS-Ad-hoc: SYNBIOTIC SE / Schlagwort(e): Insolvenz/Angespannte wirtschaftliche Situation
Hempro International GmbH beabsichtigt Antrag auf Eröffnung eines vorläufigen Insolvenzverfahrens... ► Artikel lesen | |
| TONIX PHARMACEUTICALS | 10,775 | +2,33 % | Tonix, MapLight are new Strong Buys at Raymond James on upcoming catalysts | ||
| ZEALAND PHARMA | 38,470 | +0,65 % | Transactions in Zealand Pharma shares and/or related securities by persons discharging managerial responsibilities and/or their closely associated persons | ||
| SELLAS LIFE SCIENCES | 9,300 | +0,43 % | DesignRush: Brooke Sellas Joins DesignRush Podcast on Social Media's Revenue Risk | Miami, Florida--(Newsfile Corp. - June 23, 2026) - The latest episode of the DesignRush Podcast features Brooke Sellas, founder and CEO of B Squared Media. The episode explores why companies risk... ► Artikel lesen | |
| XORTX THERAPEUTICS | 1,946 | +7,99 % | XORTX Therapeutics Inc (4): XORTX $5-million (U.S.) prospectus offering | ||
| TG THERAPEUTICS | 46,800 | -0,85 % | TG Therapeutics, Inc.: TG Therapeutics Announces Positive Topline Phase 1 Data for Subcutaneous BRIUMVI in Patients with Myasthenia Gravis and Initiation of Potential Registration Directed Randomized Phase 2 Trial | 82% of subjects achieved an MCID in their MG-ADL with a mean >4 point improvement in MG-ADL observed in Phase 1 study of Subcutaneous BRIUMVI in patients with MG (n=11) Potential registration-directed... ► Artikel lesen | |
| SOLIGENIX | 0,400 | +1,24 % | SOLIGENIX, INC.: Soligenix Announces Recent Updates and First Quarter 2026 Financial Results | PRINCETON, N.J., May 8, 2026 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing... ► Artikel lesen | |
| TALPHERA | 0,910 | 0,00 % | TALPHERA, INC. - 8-K, Current Report | ||
| SAVARA | 5,166 | -2,49 % | Savara Inc.: Savara Announces the U.K. Medicines and Healthcare Products Regulatory Agency (MHRA) Has Accepted the MOLBREEVI* Marketing Authorisation Application (MAA) for Autoimmune Pulmonary Alveolar Proteinosis (Autoimmune PAP) | -- MHRA's Acceptance Follows Acceptance/Validation of MOLBREEVI Biologics License Application (BLA) and MAA in Autoimmune PAP by the U.S. Food and Drug Administration (FDA) and the European Medicines... ► Artikel lesen | |
| SCYNEXIS | 3,770 | -1,05 % | XFRA 135: AUSSETZUNG/SUSPENSION | DAS/ DIE FOLGENDE(N) INSTRUMENT(E) IST/ SIND AB SOFORT AUSGESETZT:THE FOLLOWING INSTRUMENT(S) IS/ ARE SUSPENDED WITH IMMEDIATE EFFECT:INSTRUMENT NAME KUERZEL/SHORTCODE ISIN BIS/UNTILSCYNEXIS INC. DL... ► Artikel lesen | |
| THERIVA BIOLOGICS | 0,236 | 0,00 % | Theriva Biologics, Inc.: Theriva Biologics Announces Results from VCN-01 Phase 1 Clinical Trial in Head and Neck Cancer Published in Clinical Cancer Research | - Prolonged overall survival (OS) was observed in heavily pre-treated refractory Head & Neck Squamous Cell Carcinoma (HNSCC) patients administered IV VCN-01 prior to the immune checkpoint inhibitor... ► Artikel lesen | |
| WAVE LIFE SCIENCES | 5,100 | +0,99 % | Wave Life Sciences Ltd.: Wave Life Sciences Announces Initiation of Phase 2a Portion of INLIGHT Trial of WVE-007 (INHBE GalNAc-siRNA) for Obesity and Cardiometabolic Diseases | In Phase 1 portion of trial, WVE-007 improved body composition by inducing fat loss, including harmful visceral fat, while maintaining muscle; data continue to support once or twice-yearly dosing... ► Artikel lesen | |
| TUHURA BIOSCIENCES | 2,280 | 0,00 % | TuHURA Biosciences, Inc.: TuHURA Biosciences Files Investigational New Drug Application for Evaluation of the TBS-2025 VISTA Inhibiting Antibody in Molecularly Defined Subsets of AML and Other Blood Related Cancers | The IND is aligned with guidance previously provided by the U.S. Food and Drug Administration (FDA) on the development pathway for both monotherapy and combination... ► Artikel lesen |
Das Unternehmen TRISALUS LIFE SCIENCES INC kann der Branche Pharma zugeordnet werden. Der aktuelle Kurs liegt bei 4,360 Euro und damit -0,23 % im Minus.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu TRISALUS LIFE SCIENCES INC finden Sie auf Wallstreet Online.